TY - JOUR
T1 - Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism A Multicenter Study in Japan
AU - Nagahama Study; JPAS Study Group
AU - Ohno, Youichi
AU - Sone, Masakatsu
AU - Inagaki, Nobuya
AU - Yamasaki, Toshinari
AU - Ogawa, Osamu
AU - Takeda, Yoshiyu
AU - Kurihara, Isao
AU - Itoh, Hiroshi
AU - Umakoshi, Hironobu
AU - Tsuiki, Mika
AU - Ichijo, Takamasa
AU - Katabami, Takuyuki
AU - Tanaka, Yasushi
AU - Wada, Norio
AU - Shibayama, Yui
AU - Yoshimoto, Takanobu
AU - Ogawa, Yoshihiro
AU - Kawashima, Junji
AU - Takahashi, Katsutoshi
AU - Fujita, Megumi
AU - Watanabe, Minemori
AU - Matsuda, Yuichi
AU - Kobayashi, Hiroki
AU - Shibata, Hirotaka
AU - Kamemura, Kohei
AU - Otsuki, Michio
AU - Fujii, Yuichi
AU - Yamamoto, Koichi
AU - Ogo, Atsushi
AU - Okamura, Shintaro
AU - Miyauchi, Shozo
AU - Fukuoka, Tomikazu
AU - Izawa, Shoichiro
AU - Yoneda, Takashi
AU - Hashimoto, Shigeatsu
AU - Yanase, Toshihiko
AU - Suzuki, Tomoko
AU - Kawamura, Takashi
AU - Tabara, Yasuharu
AU - Matsuda, Fumihiko
AU - Naruse, Mitsuhide
N1 - Funding Information:
This study was conducted as a part of the JPAS (Japan Primary Aldosteronism Study) by the research grant from Japan Agency for Medical Research and Development (No. 15Aek0109122). We are also grateful to the Nagahama City Office and nonprofit organization Zeroji Club for their help in conducting the Nagahama Study. We wish to thank Dr Yukio Hirata at the Institute of Biomedical Research and Innovation Hospital and Dr Kazuaki Shimamoto at Sapporo Medical University School of Medicine for interpreting the significance of the results of this study. We also wish to thank Dr Masanobu Yamada at Gunma University, Tatsuya Kai at Saiseikai Tondabayashi Hospital, and Ryuichi Sakamoto at Saiseikai Fukuoka Hospital for collecting clinical data.
Funding Information:
This study was supported by grants-in-aid for the JPAS (Japan Primary Aldosteronism Study) from the Practical Research Project for Rare/Intractable Disease from the Japan Agency for Medical Research and Development (AMED; 15Aek0109122). This study was also supported by a grant from the Ministry of Health, Labor, and Welfare, Japan (Nanbyo-Ippan-046). The Nagahama Study was supported by a University Grant and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan; by the Center of Innovation Program and the Global University Project from Japan Science and Technology Agency; and by the Practical Research Project for Rare/Intractable Diseases and the Comprehensive Research on Aging and Health Science Research Grants for Dementia Research and Development from Japan AMED.
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2018
Y1 - 2018
N2 - There have been several clinical studies examining the factors associated with cardiovascular disease (CVD) in patients with primary aldosteronism (PA); however, their results have left it unclear whether CVD is affected by the plasma aldosterone concentration or hypokalemia. We assessed the PA database established by the multicenter JPAS (Japan Primary Aldosteronism Study) and compared the prevalence of CVD among patients with PA with that among age-, sex-, and blood pressure-matched essential hypertension patients and participants with hypertension in a general population cohort. We also performed binary logistic regression analysis to determine which parameters significantly increased the odds ratio for CVD. Of the 2582 patients with PA studied, the prevalence of CVD, including stroke (cerebral infarction, cerebral hemorrhage, or subarachnoid hemorrhage), ischemic heart disease (myocardial infarction or angina pectoris), and heart failure, was 9.4% (stroke, 7.4%; ischemic heart disease, 2.1%; and heart failure, 0.6%). The prevalence of CVD, especially stroke, was higher among the patients with PA than those with essential hypertension/ hypertension. Hypokalemia (K+ ≤3.5 mEq/L) and the unilateral subtype significantly increased adjusted odds ratios for CVD. Although aldosterone levels were not linearly related to the adjusted odds ratio for CVD, patients with plasma aldosterone concentrations ≥125 pg/mL had significantly higher adjusted odds ratios for CVD than those with plasma aldosterone concentrations <125 pg/mL. Thus, patients with PA seem to be at a higher risk of developing CVD than patients with essential hypertension. Moreover, patients with PA presenting with hypokalemia, the unilateral subtype, or plasma aldosterone concentration ≥125 pg/mL are at a greater risk of CVD and have a greater need for PA-specific treatments than others.
AB - There have been several clinical studies examining the factors associated with cardiovascular disease (CVD) in patients with primary aldosteronism (PA); however, their results have left it unclear whether CVD is affected by the plasma aldosterone concentration or hypokalemia. We assessed the PA database established by the multicenter JPAS (Japan Primary Aldosteronism Study) and compared the prevalence of CVD among patients with PA with that among age-, sex-, and blood pressure-matched essential hypertension patients and participants with hypertension in a general population cohort. We also performed binary logistic regression analysis to determine which parameters significantly increased the odds ratio for CVD. Of the 2582 patients with PA studied, the prevalence of CVD, including stroke (cerebral infarction, cerebral hemorrhage, or subarachnoid hemorrhage), ischemic heart disease (myocardial infarction or angina pectoris), and heart failure, was 9.4% (stroke, 7.4%; ischemic heart disease, 2.1%; and heart failure, 0.6%). The prevalence of CVD, especially stroke, was higher among the patients with PA than those with essential hypertension/ hypertension. Hypokalemia (K+ ≤3.5 mEq/L) and the unilateral subtype significantly increased adjusted odds ratios for CVD. Although aldosterone levels were not linearly related to the adjusted odds ratio for CVD, patients with plasma aldosterone concentrations ≥125 pg/mL had significantly higher adjusted odds ratios for CVD than those with plasma aldosterone concentrations <125 pg/mL. Thus, patients with PA seem to be at a higher risk of developing CVD than patients with essential hypertension. Moreover, patients with PA presenting with hypokalemia, the unilateral subtype, or plasma aldosterone concentration ≥125 pg/mL are at a greater risk of CVD and have a greater need for PA-specific treatments than others.
KW - Aldosterone cardiovascular diseases hyperaldosteronism myocardial ischemia stroke
UR - http://www.scopus.com/inward/record.url?scp=85047812621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047812621&partnerID=8YFLogxK
U2 - 10.1161/HYPERTENSIONAHA.117.10263
DO - 10.1161/HYPERTENSIONAHA.117.10263
M3 - Article
C2 - 29358460
AN - SCOPUS:85047812621
SN - 0194-911X
VL - 71
SP - 530
EP - 537
JO - Hypertension
JF - Hypertension
IS - 3
ER -